Yes. I think it's important that.... Again, to come back to my comment about the implementation, these costs will appear only in the future if the agreement is implemented properly. That means patent extensions should not apply to drugs already on the market. They are only to apply to new drugs that come on the market after the agreement enters into force. I think that's critical.
On May 31st, 2016. See this statement in context.